IGC IGC Pharma, Inc.
Price Chart
Executive Summary
IGC Pharma extended its existing Master Loan and Security Agreement with O-Bank Co., Ltd., maintaining a $12,000,000 credit facility. The facility fee increased from $48,000 to $60,000, but all other material terms remain substantially unchanged from the prior year's agreement. This is a routine continuation of a credit facility with no new borrowing or change in terms that would materially impact the company's financial position.
Key Financial Metrics
Actionable Insight
Routine credit facility extension with no new borrowing. Monitor future 10-Q for any draw-downs or changes in leverage, but this filing alone does not signal a change in financial health or investment thesis.
Key Facts
- IGC Pharma entered into an amendment to extend its existing Master Loan and Security Agreement with O-Bank Co., Ltd., dated June 5, 2026.
- The facility provides for a maximum aggregate limit of $12,000,000.
- Material terms remain substantially unchanged from the 2025 facility letter.
- The facility fee increased from $48,000 to $60,000.
- No new borrowing was announced; this is a continuation of existing credit arrangements.
Financial Impact
Extension of $12,000,000 credit facility with a modest $12,000 increase in annual facility fee. No new debt drawn or material change in obligations.
Risk Factors
- Interest rate terms or covenants were not disclosed and could change upon renewal or draw.
- Reliance on a single Taiwan-based lender for credit capacity.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001185185-26-002410 |
| Document: 0001185185-26-002410-index-headers.html | 0001185185-26-002410 |
| Document: 0001185185-26-002410-index.html | 0001185185-26-002410 |
| Document: 0001185185-26-002410.txt | 0001185185-26-002410 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
8-K
| $0.2980 awaiting T+20 | awaiting T+20 | — | $0.2800 (−6.04%) |
|
Apr 20, 2026
7w ago
|
8-K
| $0.3200 $0.2900 | ▲ +9.38% | ▲ +14.29% | $0.2800 (+12.50%) |
|
Mar 12, 2026
13w ago
|
8-K
| $0.2800 $0.3000 | ▼ −7.14% | ▼ −5.17% | $0.2800 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access